News

The study is designed to assess the bioavailability profile of increasing doses of PTH-1-34 combined with different amounts of 5-CNAC administered orally. The trial is being conducted in

Collaborating with Numoda will allow Dor to take full advantage of a comprehensive scope of services including using their industry benchmarking capabilities to develop an accurate operational and

Novelos’s NOV-002 has demonstrated positive results in Phase II trials for other oncology indications. Overall, Novelos filed more than 30 patent applications worldwide. Together, these will provide broad

The randomized and double-blind trial is expected to enroll 210 adolescents, between the ages of 12 to 17, who will receive doses of 10ug, 15ug or 30ug, and

The primary objective of the study is to assess the overall response rate to the combination of bavituximab with a standard regimen of carboplatin and paclitaxel in non-small

Anika’s Monovisc is a single-injection viscosupplement therapy approved in the European economic area for treatment of osteoarthritis symptoms in all synovial joints. Other viscosupplements are indicated for specific

Included in the submission was a 12-week, multi-center, open-label, randomized, parallel-group study of 111 adolescent gastroesophageal reflux disease (GERD) patients. In this study, Aciphex was well tolerated in

The agreement grants to EWA Government Systems (EWA GSI) the right to market both the gel and powder forms of CellerateRx and will be compensated strictly on a

Orphan drug designation offers significant benefits to Hana Biosciences, including financial incentives and market exclusivity for a period of seven years. Hana is currently conducting a Phase II